Spots Global Cancer Trial Database for Pembrolizumab for Newly Diagnosed Glioblastoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Pembrolizumab for Newly Diagnosed Glioblastoma
Official Title: Pembrolizumab for Newly Diagnosed Glioblastoma: a Prospective, Open-label, Single-arm, Multicenter Phase II Study
Study ID: NCT03899857
Conditions
Interventions
Study Description
Brief Summary: The study explores the addition of pembrolizumab to temozolomide-based radiotherapy in patients with newly diagnosed glioblastoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University Hospital Bern / Inselspital, Bern, , Switzerland
University Hospital Lausanne, CHUV, Lausanne, , Switzerland
University Hospital Zurich, Zürich, , Switzerland
Contact Details
Name: Patrick Roth, MD
Affiliation: University of Zurich
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
